Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
Tamibarotene has been used to study its mode of action and therapeutic potential.
Biochem/physiol Actions
Tamibarotene is a synthetic retinoid drug, highly stable and potent inducer of differentiation than ATRA (all-trans retinoic acid). It showed mild growth inhibition in myeloma cells and HUVECs (human umbilical vein endothelial cell).
Tamibarotene (Am80) is a RAR α agonist. Tamibarotene was developed to overcome resistance to ATRA and is currently approved in Japan for treatment of recurrent acute promyelocytic leukemia (APL). The compound induces HL-60 cells differentiation and apoptosis. Similarly to TTNPB, the compound neither binds to nor transactivates the RXRs. In contrast to TTNPB (pan RAR agonist), Tamibarotene is rather specific toward RAR α. The compound is approximate 10 times more potent than ATRA.
Features and Benefits
This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Packaging
5, 25 mg in glass bottle
Preparation Note
Tamibarotene is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :